Clinical trial · Observational
Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer
CPET-Panc: Exercise Testing in Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cardiopulmonary exercise testing (CPET) has been shown to be superior to American Society of Anaesthetist classification (ASA) in predicting peri-operative risk. The most common performance status used is the World Health Organisation (WHO) (0-4), with a clinician agreed differentiation of the subsets of 0-2 and 3-4; variability also exists within these subsets. With this there rises a concern that fit older patients may not be offered appropriate chemotherapy treatment. This observational study will assess whether cardiopulmonary exercise testing (CPET) offers additional benefit over that of WHO Performance status (PS) in the assessment of patients fitness for palliative chemotherapy for pancreatic cancer, by identifying those patients who might survive longer and tolerate chemotherapy better, thus predicting their outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiopulmonary Exercise Test | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cardiopulmonary Exercise Test
- description
- A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
- interventionNames
- Device: Cardiopulmonary Exercise Test
Primary outcomes (4)
- measure
- Survival at 6 months (followed up for 12mths)
- timeFrame
- 6 months
- description
- AUROC (Area under Receiver Operating Characteristic) for WHO (0-4) and WHO + CPET. A logistic regression model will be constructed, one with WHO PS and VO2 at AT (ml/kg/min).
- measure
- Survival at 6 months (followed up for 12mths)
- timeFrame
- 6 months
- description
- AUROC for WHO and WHO + CPET: A logistic regression model will be constructed with WHO PS and VO2 max (ml/kg/min).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven pancreatic cancer * Due to commence palliative chemotherapy (including as part of a Clinical Trial of an Investigational Medicinal Product (CTIMP)). * Able to undertake CPET * Expected life expectancy \>3 months * Age 18+ Exclusion Criteria: • Haemoglobin \<10g/L Absolute contraindications for cardiopulmonary exercise testing: * Acute myocardial infarction (3-5 days) * Unstable angina * Uncontrolled arrhythmias causing symptoms or hemodynamic comprise * Syncope * Active endocarditis * Acute myocarditis or pericarditis * Symptomatic severe aortic stenosis * Uncontrolled heart failure * Acute pulmonary embolus or pulmonary infarction * Thrombosis of lower extremities * Suspected dissecting aneurysm * Uncontrolled asthma * Pulmonary edema * Room air desaturation at rest ≤85% * Respiratory failure * Acute noncardiopulmonary disorder that may aggravated by exercise (i.e. renal failure, thyrotoxicosis) * Mental impairment leading to inability to cooperate Relative contraindications for cardiopulmonary exercise testing: * Left main coronary stenosis or its equivalent * Moderate stenotic valvular heart disease * Severe untreated arterial hypertension at rest (\>200mm Hg systolic, \> 120mm Hg diastolic) * Tachyarrhythmias or bradyarrhythmias * High-degree atrioventricular block * Hypertrophic cardiomyopathy * Significant pulmonary hypertension * Advanced or complicated pregnancy * Orthopaedic impairment that compromises
References
Publications (0)
Data not yet available